Get the Stockscreener App
1.03
0.00%
0.00
After Hours:
.99
-0.04
-3.88%
Clearmind Medicine Inc stock is traded at $1.03, with a volume of 40,640.
It is up +0.00% in the last 24 hours and down -9.65% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$1.03
Open:
$1.02
24h Volume:
40,640
Relative Volume:
0.37
Market Cap:
$5.29M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0241
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-3.74%
1M Performance:
-9.65%
6M Performance:
-16.26%
1Y Performance:
-10.43%
1-Day Range:
$0.9993
$1.04
1-Week Range:
$0.9993
$1.08
52-Week Range:
$0.9512
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.03 | 5.29M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind launches data system for alcohol addiction trial - Investing.com
Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq
Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks
Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance
Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa
Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US - MarketScreener
Clearmind’s AUD drug candidate arrives in the U.S. for trials - Investing.com
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - The Manila Times
Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder - Nasdaq
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - TradingView
Clearmind and Polyrizon partner on nasal drug delivery By Investing.com - Investing.com South Africa
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon - Nasdaq
Clearmind and Polyrizon partner on nasal drug delivery - Investing.com
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination - The Manila Times
Clearmind begins phase I/IIa trial for AUD treatment - Investing.com Australia
Clearmind Medicine Advances CMND-100 To Clinical Trials For Alcohol Use Disorder - Nasdaq
Clearmind Medicine Initiates First Clinical Trial Of CMND-100 For Alcohol Use Disorder Treatment - Nasdaq
Clearmind begins phase I/IIa trial for AUD treatment By Investing.com - Investing.com South Africa
Clearmind Begins Human Trials for Potential Psychedelic Treatment for Alcohol Abuse Patients - Marketscreener.com
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder Patients - Nasdaq
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in ... - The Bakersfield Californian
Clearmind Medicine (CMND) versus Its Peers Head to Head Contrast - Defense World
Clearmind secures South Korean patent for addiction therapy By Investing.com - Investing.com Australia
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves - Financial Content
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
Clearmind secures South Korean patent for addiction therapy - Investing.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
SciSparc Advances Cocaine Treatment Patent Following Successful Preclinical Data - StockTitan
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
Clearmind Medicine Announces Publication Of Patent For Cocaine Addiction Psychedelic Combination Treatment In South Korea - MENAFN.COM
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Cocaine Addiction - Nasdaq
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
Obesity Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Head-To-Head Comparison: Clearmind Medicine (CMND) versus The Competition - Defense World
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
Clearmind Medicine Secures Patent For Psychedelic Combination Therapy In Mexico - Nasdaq
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Binge Behavior - Nasdaq
Novel Psychedelic-Based Therapy Gets Patent Green Light: Targets Multiple Addictions - StockTitan
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):